A multicenter, double-blind, randomized, placebo-controlled study on the effect of ultra-low dose transdermal estradiol (Menostar) [Bayer] on the incidence and severity of hot flushes, other menopausal symptoms and on well-being in postmenopausal Asian women over 12 weeks

Trial Profile

A multicenter, double-blind, randomized, placebo-controlled study on the effect of ultra-low dose transdermal estradiol (Menostar) [Bayer] on the incidence and severity of hot flushes, other menopausal symptoms and on well-being in postmenopausal Asian women over 12 weeks

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs Estradiol (Primary)
  • Indications Hot flashes; Menopausal syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 01 Oct 2009 Results published in Climacteric.
    • 29 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top